Combining the chemotherapy streptozotocin with various mTOR inhibitors was found to effectively target tumors in preclinical studies for pancreatic neuroendocrine tumors (pNETs).
Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.
Diagnosis of acute myeloid leukemia (AML) is pivoted around cytogenetic analysis of patient bone marrow or peripheral blood cultures. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues is based on cytogenetic features along with other clinical, morphological, and immunophenotypic characteristics.
Over the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.
Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
The incidence of thyroid cancer, which is now the most rapidly increasing endocrine malignancy, has been increasing at a rate of 3% to 5% per year, resulting in a near doubling in the past 30 years.
Clinicians will soon face challenging decisions on which immunotherapies to prescribe their patients, and in what sequence or combination.
Katharine Yao, MD, gives an overview of an analysis that looked at patient preferences prior to surgery.
It is rare that treatment guidelines make sweeping changes to treatment recommendations, yet the American Society of Breast Surgeons is urging that the National Comprehensive Cancer Network guidelines on breast cancer treatment be changed to indicate that genetic testing be offered to all patients with breast cancer.
Findings from a recent phase II study showed the PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme (GBM).
Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.
Kei Muro, MD, discusses phase II and III trials which examine pembrolizumab as a treatment for patients with advanced gastric cancer.
Alexander Drilon, MD, discussed updated findings with larotrectinib in <em>NTRK</em> fusion–positive tumors and entrectinib in <em>ROS1</em> fusion–positive NSCLC.<br />
Knowledge of genetic expression of melanocytic lesions significantly reduced the number of indeterminate diagnoses made by dermatopathologists.
Patients with a certain type of oral human papilloma virus (HPV) have an increased risk of developing head and neck squamous cell carcinoma, as well as oropharyngeal cancer, according to a new study.
Targeted therapy through the use of antibody drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.
The growth of the oncology drug pipeline has fueled the emergence of new oral therapies. While these therapies make treatment more convenient, when compared with traditional infused chemotherapy regimens, they also present new challenges, particularly in the area of adherence.
Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.